177 related articles for article (PubMed ID: 35094009)
1. SMARCA4 biology in alveolar rhabdomyosarcoma.
Bharathy N; Cleary MM; Kim JA; Nagamori K; Crawford KA; Wang E; Saha D; Settelmeyer TP; Purohit R; Skopelitis D; Chang K; Doran JA; Kirschbaum CW; Bharathy S; Crews DW; Randolph ME; Karnezis AN; Hudson-Price L; Dhawan J; Michalek JE; Ciulli A; Vakoc CR; Keller C
Oncogene; 2022 Mar; 41(11):1647-1656. PubMed ID: 35094009
[TBL] [Abstract][Full Text] [Related]
2. Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type.
Karnezis AN; Wang Y; Ramos P; Hendricks WP; Oliva E; D'Angelo E; Prat J; Nucci MR; Nielsen TO; Chow C; Leung S; Kommoss F; Kommoss S; Silva A; Ronnett BM; Rabban JT; Bowtell DD; Weissman BE; Trent JM; Gilks CB; Huntsman DG
J Pathol; 2016 Feb; 238(3):389-400. PubMed ID: 26356327
[TBL] [Abstract][Full Text] [Related]
3. Residual complexes containing SMARCA2 (BRM) underlie the oncogenic drive of SMARCA4 (BRG1) mutation.
Wilson BG; Helming KC; Wang X; Kim Y; Vazquez F; Jagani Z; Hahn WC; Roberts CW
Mol Cell Biol; 2014 Mar; 34(6):1136-44. PubMed ID: 24421395
[TBL] [Abstract][Full Text] [Related]
4. SWI/SNF Complex-deficient Undifferentiated/Rhabdoid Carcinomas of the Gastrointestinal Tract: A Series of 13 Cases Highlighting Mutually Exclusive Loss of SMARCA4 and SMARCA2 and Frequent Co-inactivation of SMARCB1 and SMARCA2.
Agaimy A; Daum O; Märkl B; Lichtmannegger I; Michal M; Hartmann A
Am J Surg Pathol; 2016 Apr; 40(4):544-53. PubMed ID: 26551623
[TBL] [Abstract][Full Text] [Related]
5. Switch/sucrose-non-fermentable (SWI/SNF) complex (SMARCA4, SMARCA2, INI1/SMARCB1)-deficient colorectal carcinomas are strongly associated with microsatellite instability: an incidence study in 4508 colorectal carcinomas.
Ahadi MS; Fuchs TL; Clarkson A; Sheen A; Sioson L; Chou A; Gill AJ
Histopathology; 2022 May; 80(6):906-921. PubMed ID: 34951482
[TBL] [Abstract][Full Text] [Related]
6. High expression of SMARCA4 or SMARCA2 is frequently associated with an opposite prognosis in cancer.
Guerrero-Martínez JA; Reyes JC
Sci Rep; 2018 Feb; 8(1):2043. PubMed ID: 29391527
[TBL] [Abstract][Full Text] [Related]
7. SWI/SNF complex-deficient soft tissue neoplasms: An update.
Schaefer IM; Hornick JL
Semin Diagn Pathol; 2021 May; 38(3):222-231. PubMed ID: 32646614
[TBL] [Abstract][Full Text] [Related]
8. Synthetic lethality: targeting SMARCA2 ATPase in SMARCA4-deficient tumors - a review of patent literature from 2019-30 June 2023.
Reichl KD; Lee ECY; Gopalsamy A
Expert Opin Ther Pat; 2024 Mar; 34(3):159-169. PubMed ID: 38578210
[TBL] [Abstract][Full Text] [Related]
9. NELL1, whose high expression correlates with negative outcomes, has different methylation patterns in alveolar and embryonal rhabdomyosarcoma.
Tombolan L; Poli E; Martini P; Zin A; Romualdi C; Bisogno G; Lanfranchi G
Oncotarget; 2017 May; 8(20):33086-33099. PubMed ID: 28380437
[TBL] [Abstract][Full Text] [Related]
10. Involvement of the chromatin-remodeling factor BRG1/SMARCA4 in human cancer.
Medina PP; Sanchez-Cespedes M
Epigenetics; 2008; 3(2):64-8. PubMed ID: 18437052
[TBL] [Abstract][Full Text] [Related]
11. Differential expression of Snail1 transcription factor and Snail1-related genes in alveolar and embryonal rhabdomyosarcoma subtypes.
Püsküllüoglu M; Lukasiewicz E; Miekus K; Jarocha D; Majka M
Folia Histochem Cytobiol; 2010 Dec; 48(4):671-7. PubMed ID: 21478114
[TBL] [Abstract][Full Text] [Related]
12. The HDAC3-SMARCA4-miR-27a axis promotes expression of the
Bharathy N; Berlow NE; Wang E; Abraham J; Settelmeyer TP; Hooper JE; Svalina MN; Ishikawa Y; Zientek K; Bajwa Z; Goros MW; Hernandez BS; Wolff JE; Rudek MA; Xu L; Anders NM; Pal R; Harrold AP; Davies AM; Ashok A; Bushby D; Mancini M; Noakes C; Goodwin NC; Ordentlich P; Keck J; Hawkins DS; Rudzinski ER; Chatterjee B; Bächinger HP; Barr FG; Liddle J; Garcia BA; Mansoor A; Perkins TJ; Vakoc CR; Michalek JE; Keller C
Sci Signal; 2018 Nov; 11(557):. PubMed ID: 30459282
[TBL] [Abstract][Full Text] [Related]
13. Loss of the SWI/SNF-ATPase subunit members SMARCF1 (ARID1A), SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1) in oesophageal adenocarcinoma.
Schallenberg S; Bork J; Essakly A; Alakus H; Buettner R; Hillmer AM; Bruns C; Schroeder W; Zander T; Loeser H; Gebauer F; Quaas A
BMC Cancer; 2020 Jan; 20(1):12. PubMed ID: 31906887
[TBL] [Abstract][Full Text] [Related]
14. SMARCA2-deficiency confers sensitivity to targeted inhibition of SMARCA4 in esophageal squamous cell carcinoma cell lines.
Ehrenhöfer-Wölfer K; Puchner T; Schwarz C; Rippka J; Blaha-Ostermann S; Strobl U; Hörmann A; Bader G; Kornigg S; Zahn S; Sommergruber W; Schweifer N; Zichner T; Schlattl A; Neumüller RA; Shi J; Vakoc CR; Kögl M; Petronczki M; Kraut N; Pearson MA; Wöhrle S
Sci Rep; 2019 Aug; 9(1):11661. PubMed ID: 31406271
[TBL] [Abstract][Full Text] [Related]
15. The SWI/SNF chromatin-remodeling complex status in renal cell carcinomas with sarcomatoid or rhabdoid features.
Kinoshita F; Kohashi K; Sugimoto M; Takamatsu D; Kiyozawa D; Eto M; Oda Y
Virchows Arch; 2020 Nov; 477(5):651-660. PubMed ID: 32447490
[TBL] [Abstract][Full Text] [Related]
16. SMARCA4: Current status and future perspectives in non-small-cell lung cancer.
Tian Y; Xu L; Li X; Li H; Zhao M
Cancer Lett; 2023 Feb; 554():216022. PubMed ID: 36450331
[TBL] [Abstract][Full Text] [Related]
17. Activation of the hedgehog pathway confers a poor prognosis in embryonal and fusion gene-negative alveolar rhabdomyosarcoma.
Zibat A; Missiaglia E; Rosenberger A; Pritchard-Jones K; Shipley J; Hahn H; Fulda S
Oncogene; 2010 Dec; 29(48):6323-30. PubMed ID: 20818440
[TBL] [Abstract][Full Text] [Related]
18.
Concepcion CP; Ma S; LaFave LM; Bhutkar A; Liu M; DeAngelo LP; Kim JY; Del Priore I; Schoenfeld AJ; Miller M; Kartha VK; Westcott PMK; Sánchez-Rivera FJ; Meli K; Gupta M; Bronson RT; Riely GJ; Rekhtman N; Rudin CM; Kim CF; Regev A; Buenrostro JD; Jacks T
Cancer Discov; 2022 Feb; 12(2):562-585. PubMed ID: 34561242
[No Abstract] [Full Text] [Related]
19. PRC2-mediated repression of SMARCA2 predicts EZH2 inhibitor activity in SWI/SNF mutant tumors.
Januario T; Ye X; Bainer R; Alicke B; Smith T; Haley B; Modrusan Z; Gould S; Yauch RL
Proc Natl Acad Sci U S A; 2017 Nov; 114(46):12249-12254. PubMed ID: 29087303
[TBL] [Abstract][Full Text] [Related]
20. FGFR4 blockade exerts distinct antitumorigenic effects in human embryonal versus alveolar rhabdomyosarcoma.
Crose LE; Etheridge KT; Chen C; Belyea B; Talbot LJ; Bentley RC; Linardic CM
Clin Cancer Res; 2012 Jul; 18(14):3780-90. PubMed ID: 22648271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]